Agios to take over Al­ny­lam’s pre­clin­i­cal siR­NA blood dis­or­der as­set in a deal worth $147.5M

Agios and Al­ny­lam have agreed on an ex­clu­sive glob­al li­cens­ing deal worth $147.5 mil­lion for Agios to take over the de­vel­op­ment and com­mer­cial­iza­tion of a poly­cythemia ve­ra pre­clin­i­cal siR­NA can­di­date.

Agios is pay­ing $17.5 mil­lion up­front, with Al­ny­lam re­ceiv­ing up to $130 mil­lion for de­vel­op­ment and reg­u­la­to­ry mile­stone pay­ments, on top of sales mile­stones and tiered roy­al­ties, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER